Press coverage about Henry Schein (NASDAQ:HSIC) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Henry Schein earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.0610565662258 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Henry Schein (NASDAQ HSIC) traded up $0.04 during mid-day trading on Thursday, hitting $72.18. 1,185,050 shares of the stock traded hands, compared to its average volume of 1,283,667. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. Henry Schein has a twelve month low of $65.28 and a twelve month high of $93.50. The stock has a market cap of $11,217.53, a price-to-earnings ratio of 20.80, a P/E/G ratio of 1.86 and a beta of 1.00.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The firm had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the company earned $0.84 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. research analysts expect that Henry Schein will post 3.6 EPS for the current year.

Henry Schein declared that its board has authorized a stock repurchase program on Monday, September 18th that authorizes the company to buyback $400.00 million in shares. This buyback authorization authorizes the company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

A number of equities analysts recently commented on the stock. UBS Group reissued a “buy” rating on shares of Henry Schein in a research note on Friday, September 15th. Piper Jaffray Companies raised shares of Henry Schein from a “neutral” rating to an “overweight” rating in a research note on Friday, September 15th. Jefferies Group reissued a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a research note on Friday, October 20th. Robert W. Baird set a $95.00 price objective on shares of Henry Schein and gave the stock a “buy” rating in a research note on Thursday, October 19th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a research note on Thursday, October 19th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. Henry Schein has an average rating of “Hold” and a consensus target price of $86.21.

In related news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the transaction, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.19% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with Analyst Ratings Network's FREE daily email newsletter.